Nivolumab in the Treatment of Cancer

Nivolumab (Opdivo) is a fully human IgG4 monoclonal antibody that targets the programmed cell death-1 (PD-1) immune checkpoint receptor on T lymphocytessynapse.patsnap.comsynapse.patsnap.com. By blocking PD-1, nivolumab “releases the brakes” on the immune system, enabling T cells to mount a stronger anti-tumor responsesynapse.patsnap.com. Since its initial approval in 2014, nivolumab has […]